RxDoctor Payments Data

Amin Rahmatullah, MD

Cardiovascular Disease · Minneapolis, MNNPI 1144268764

Payments from drug & device makers

$27,766in general payments, 2019–2025

Across 65 payments — averaging $427.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Canon Medical Informatics, Inc.$12K
  • Novartis$11K
  • Abbott$2K
  • Heartflow, Inc.$1K
  • Cvrx, Inc.$843
  • Edwards Lifesciences$196
  • plus $529 from 6 others

What the payments were for

  • Speaking & faculty fees$11,97173%
  • Travel & lodging$2,07813%
  • Food & beverage$2,30714%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,766 in reported general payments places this provider in the 70th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$57,288
Medicare patients
502
Services billed
952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan73$947,626
Tyvaso DpiTreprostinil19$836,064
UptraviSelexipag27$679,505
AdempasRiociguat12$165,615
EliquisApixaban91$90,984
EntrestoSacubitril/Valsartan52$67,795
XareltoRivaroxaban44$54,583
JardianceEmpagliflozin44$44,359
Sildenafil Citrate18$5,209
Metoprolol Succinate185$3,573
Bumetanide50$2,206
Rosuvastatin Calcium146$1,906
Atorvastatin Calcium76$1,170
Carvedilol102$1,083
Losartan Potassium88$1,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$11,410$67,79552 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 451 cardiovascular disease providers in Minnesota.

Other cardiovascular disease in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →